Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy

A multiplex apolipoprotein panel led to better prediction of MACE and all-cause death, beyond lipids, in patients with postacute coronary syndrome on optimized statin therapy. The panel also predicts the treatment benefit of alirocumab. Further validation of this approach is now needed, and if confirmed and improved, it could lead to better disease prediction and management in the future.

Authors

Institutions

Publication Details

Journal
Arteriosclerosis Thrombosis and Vascular Biology
Published
2025-09-25
DOI
https://doi.org/10.1161/atvbaha.124.322336
Citations
2
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
4.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy

Philippe Gabríel Steg, J. Wouter Jukema, Deepak L. Bhatt, Christa M. Cobbaert et al.
2 citations
Arteriosclerosis Thrombosis and Vascular Biology
Lipoproteins and Cardiovascular Health
4.01
article

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy

Philippe Gabríel Steg, J. Wouter Jukema, Deepak L. Bhatt, Christa M. Cobbaert, Fred P.H.T.M. Romijn, Shaun G. Goodman, Vera Bittner, Esther Reijnders, Robert A. Harrington, Patrick M. Bossuyt, Rafael Dı́az, Harvey D. White, Gregory G. Schwartz, Michael Szarek, L. Renee Ruhaak, Stella Trompet, Sergio Fazio, Irena Stevanovic
article en
2 citations

Abstract

A multiplex apolipoprotein panel led to better prediction of MACE and all-cause death, beyond lipids, in patients with postacute coronary syndrome on optimized statin therapy. The panel also predicts the treatment benefit of alirocumab. Further validation of this approach is now needed, and if confirmed and improved, it could lead to better disease prediction and management in the future.

Arteriosclerosis Thrombosis and Vascular BiologyVol. 45(11)
St. Michael's Hospital (CA), Inserm (FR), SUNY Downstate Health Sciences University (US), Regeneron (United States) (US), Université Paris Cité (FR), Cornell University (US), Leiden University Medical Center (NL), The Medical Center of Aurora (US), Sanofi (France) (FR), University of Alabama at Birmingham (US), Greenlane Clinical Centre (NZ), Assistance Publique – Hôpitaux de Paris (FR), Mount Sinai Hospital (US), Netherlands Heart Institute (NL), Canadian VIGOUR Centre (CA), Estudios Clínicos Latinoamérica (AR), Hôpital Bichat-Claude-Bernard (FR), Instituto Cardiovascular de Rosario (AR), GGD Amsterdam (NL), University of Colorado Denver (US)
Openalex Percentile: Top 6%
Lipoproteins and Cardiovascular Health
4.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.